Sharda Cropchem Q1 Consolidated Net Profit Falls to ₹88 Crore vs ₹140 Crore YoY

Market snapshot: Sharda Cropchem Limited announced its Q1 FY27 results for the quarter ended June 30, 2026, reporting a 38.46% YoY decline in consolidated net profit to ₹88 crore. However, the company delivered strong operational performance, with revenue increasing by 9.04% YoY to ₹1,074 crore and EBITDA rising by 25.35% YoY to ₹178 crore. The drop in bottom-line profitability was primarily driven by normalized foreign exchange gains.

Data Snapshot

• Consolidated revenue grew ≈9.04% YoY to ₹1,074 crore from ₹985 crore in Q1 FY26.
• Consolidated EBITDA increased ≈25.35% YoY to ₹178 crore, with EBITDA margins expanding 220 bps to 16.6% from 14.4%.
• Consolidated PAT fell ≈38.46% YoY to ₹88 crore from ₹143 crore, driven by lower non-operating income.

What's Changed

• Sharda Cropchem announced its Q1 FY27 results on July 29, 2026, revealing strong operational metrics but a normalized bottom-line due to external non-operating factors.
• Shareholding disclosures published on July 16, 2026, revealed that seasoned investor Dolly Khanna's stake in Sharda Cropchem slipped below the 1% threshold from 1.09% in Q4 FY26, indicating a potential exit or trim.
• On July 14, 2026, the company scheduled its 23rd Annual General Meeting (AGM) for August 14, 2026, to adopt the audited financial statements of FY26.

Key Takeaways

• Operational momentum remains robust with consolidated revenue up 9% YoY to ₹1,074 crore.
• EBITDA performance was exceptional, rising 25% YoY to ₹178 crore, demonstrating that core chemical distribution operations are expanding profitably.
• A decline in foreign exchange gains to ₹7 crore, compared to ₹73 crore in Q1 FY26, was the primary factor dragging down Net Profit.
• The balance sheet remains in pristine condition, being completely debt-free with substantial liquid assets of ₹767 crore as of June 30, 2026.
• Product pipeline is growing steadily with total registrations reaching 3,016, alongside 1,027 registrations in the pipeline.

SAHI Perspective

Sharda Cropchem's Q1 FY27 results reveal strong operational health. The headline net profit drop of 38.46% is likely to draw negative retail attention, but a deeper analysis shows that core operating performance is on an uptrend. Operating EBITDA rose 25.35% and operating margins expanded by 220 bps, validating a structural recovery in demand. The profit contraction is entirely attributable to non-operating items, specifically a sharp fall in forex gains from ₹73 crore last year to ₹7 crore this quarter. Since forex swings are volatile and non-core, the robust operational execution is the more sustainable trend.

Market Implications

The immediate stock reaction might be neutral to negative due to the headline PAT drop. However, institutional buyers are likely to view the 25% EBITDA expansion and structural margin improvements as a positive signal. Additionally, the company's strong debt-free balance sheet and cash cushion of ₹767 crore will limit any significant downside.

Trading Signals

Market Bias: Neutral

Core operations are structurally sound with EBITDA growing 25.35% YoY to ₹178 crore, but volatile non-operating forex metrics dragged net profit down 38.46% YoY to ₹88 crore. We maintain a neutral bias until the market absorbs this divergence.

Overweight: Agrochemicals, Crop Protection

Underweight: Foreign Exchange Sensitive Exporters

Trigger Factors:

• Stabilization of global agrochemical pricing and crop protection demand.
• Forex rate movements impacting non-operating yields in upcoming quarters.
• Execution and approval progress of the 1,027 registrations in the pipeline.

Time Horizon: Near-term (0-3 months)

Industry Context

The global generic crop protection and agrochemical market is gradually emerging from a period of heavy destocking and pricing pressure. Sharda Cropchem's unique asset-light sourcing and global marketing model allows it to remain highly flexible compared to capital-heavy manufacturers. The 9% growth in revenue and 25% rise in EBITDA suggest that industry demand is beginning to normalize, particularly across key regions such as Europe and NAFTA, where Sharda has a strong registration presence.

Key Risks to Watch

• Currency Volatility: With a heavy export profile, Sharda remains highly vulnerable to currency fluctuations, which impacted profitability this quarter.
• Regulatory Delays: Delays in obtaining product registrations in regulated markets could slow down the execution of the pipeline.
• Seasonal Monsoon Trends: While structurally diversified, the domestic business remains dependent on monsoon progress in India.

Recent Developments

On July 29, 2026, Sharda Cropchem announced its Q1 FY27 results, showing a 9% increase in consolidated revenue to ₹1,074 crore and a 38% drop in PAT to ₹88 crore. On July 14, 2026, the company scheduled its 23rd AGM for August 14, 2026. This follows its FY26 full-year results announced on May 13, 2026, where consolidated PAT more than doubled to ₹681 crore, and a final dividend of ₹9 per share was declared.

Closing Insight

While the headline drop in net profit might seem concerning, Sharda Cropchem's core operational recovery is well-entrenched. Investors should focus on the expanding EBITDA margins and the massive ₹767 crore cash reserves that provide substantial balance sheet security.

High Performance Trading with SAHI.